Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the PK, tolerability, and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.
The study duration will be up to 40 days, including Screening, Baseline, Study Period, and EOS visit assessments.
Rupatadine 10 mg tablet will be administered as single dose.